A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients

Kayaaslan, Bircan; Akinci, Esragul; Ari, Alpay; Tufan, Zeliha; Alpat, Saygin; Gunal, Ozgur; Tosun, Selma; Guner, Rahmet; Tabak, ÖMER

doi:10.1016/j.clinre.2017.06.008

A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients

Kayaaslan B., Akinci E., Ari A., Tufan Z. K., Alpat S. N., Gunal O., ...Daha Fazla

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, cilt.42, sa.1, ss.40-47, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 42 Sayı: 1
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.clinre.2017.06.008
Dergi Adı: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.40-47
Anahtar Kelimeler: Entecavir versus Tenofovir, Chronic Hepatitis B (CHB), Hepatitis B Virus (HBV), Efficacy, Predictors of response, DISOPROXIL FUMARATE, CLINICAL-PRACTICE, EFFICACY, THERAPY
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression.